$SI News

Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026

Transcript: Shoulder Innovations Q2 2026 Earnings Conference Call

BTIG Maintains Buy on Shoulder Innovations, Raises Price Target to $27

Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Shoulder Innovations Receives FDA Clearance For Its N-22 Humeral Head

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Shoulder Innovations Enters Into Exclusive Collaboration With ALM Ortho For Bespoke Shoulder Implant; Financial Terms Remain Confidential

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

Shoulder Innovations Enters Into A Settlement Agreement With Catalyst Orthoscience To Resolve All Outstanding Patent Litigation Between The Two Companies

Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference

Shoulder Innovations (SI) Price Target Increased by 14.13% to 26.78

UBS Maintains Buy on Shoulder Innovations, Raises Price Target to $28

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations Files $300M Mixed Securities Shelf Prospectus And Registers Resale Of 8,103,026 Common Shares By Selling Stockholders

Piper Sandler Reiterates Overweight on Shoulder Innovations, Raises Price Target to $25

BTIG Maintains Buy on Shoulder Innovations, Raises Price Target to $26

Shoulder Innovations Inc (SI) (Q2 2026) Earnings Call Highlights: Revenue Surges 56% as ...

Shoulder Innovations, Inc. (SI) Reports Q2 Loss, Beats Revenue Estimates